Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Zamvil

Showing results (21-30 of 253) with videos related to

Pageof 26
Sort By:
Science Translational Medicine|October 12, 2018
T cells take aim at a ubiquitous autoantigen in multiple sclerosisJoseph J Sabatino, Scott S Zamvil
The New England Journal of Medicine|January 27, 2021
Antigen Presentation by B Cells in Multiple SclerosisScott S Zamvil, Stephen L Hauser
Annals of Neurology|September 19, 2019
Do maternal anti-N-methyl-D-aspartate receptor antibodies promote development of neuropsychiatric disease in children?Anne-Katrin Pröbstel, Scott S Zamvil
Current Topics in Microbiology and Immunology|January 29, 2008
Statins and demyelinationM S Weber, S S Zamvil
Brain : a Journal of Neurology|June 26, 2016
Your nose knows how to target brain inflammationRyan C Winger, Scott S Zamvil
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|October 9, 2007
Neuroimmunotherapeutics comes of ageRichard M Ransohoff, Scott S Zamvil
Nature Immunology|October 12, 2023
Targeting PGLYRP1 in cancer and autoimmunityCarson E Moseley, Scott S Zamvil
Neurology(R) Neuroimmunology & Neuroinflammation|June 24, 2017
Aryl hydrocarbon receptor activity may serve as a surrogate marker for MS disease activityJoseph J Sabatino, Scott S Zamvil
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 22, 2020
New cases of vasculitis after alemtuzumabChristina J Azevedo, Scott S Zamvil
Neurology(R) Neuroimmunology & Neuroinflammation|August 12, 2024
Should We Measure CSF Complement Levels in Patients With MOGAD?Carson E Moseley, Scott S Zamvil
Pageof 26

Showing results (21-30 of 253) with videos related to

Sort By:
Pageof 26
Science Translational Medicine|October 12, 2018
T cells take aim at a ubiquitous autoantigen in multiple sclerosisJoseph J Sabatino, Scott S Zamvil
The New England Journal of Medicine|January 27, 2021
Antigen Presentation by B Cells in Multiple SclerosisScott S Zamvil, Stephen L Hauser
Annals of Neurology|September 19, 2019
Do maternal anti-N-methyl-D-aspartate receptor antibodies promote development of neuropsychiatric disease in children?Anne-Katrin Pröbstel, Scott S Zamvil
Current Topics in Microbiology and Immunology|January 29, 2008
Statins and demyelinationM S Weber, S S Zamvil
Brain : a Journal of Neurology|June 26, 2016
Your nose knows how to target brain inflammationRyan C Winger, Scott S Zamvil
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|October 9, 2007
Neuroimmunotherapeutics comes of ageRichard M Ransohoff, Scott S Zamvil
Nature Immunology|October 12, 2023
Targeting PGLYRP1 in cancer and autoimmunityCarson E Moseley, Scott S Zamvil
Neurology(R) Neuroimmunology & Neuroinflammation|June 24, 2017
Aryl hydrocarbon receptor activity may serve as a surrogate marker for MS disease activityJoseph J Sabatino, Scott S Zamvil
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 22, 2020
New cases of vasculitis after alemtuzumabChristina J Azevedo, Scott S Zamvil
Neurology(R) Neuroimmunology & Neuroinflammation|August 12, 2024
Should We Measure CSF Complement Levels in Patients With MOGAD?Carson E Moseley, Scott S Zamvil
Pageof 26